Hemolytic Uremic Syndrome: Understanding Soliris Infusion Therapy
Atypical HUS is rare and serious, affecting the kidneys and blood vessels. Soliris was the first therapy built to target the underlying immune mechanism directly.
What is hemolytic uremic syndrome?
Atypical hemolytic uremic syndrome (aHUS) is a rare, serious condition in which part of the immune system (the complement system) becomes overactive and damages small blood vessels, particularly in the kidneys. This can lead to reduced platelet counts, red blood cell destruction, and kidney injury.
Symptoms can include fatigue, easy bruising, decreased urination, swelling, and confusion, and the condition can progress quickly without treatment.
How infusion therapy helps
Soliris (eculizumab) was the first infusion therapy approved specifically for aHUS. It works by blocking part of the complement system responsible for the blood vessel damage, addressing the disease at its immune root rather than just treating kidney symptoms as they appear.
Treatment typically starts with weekly infusions before moving to a maintenance schedule every two weeks, with close monitoring of blood counts and kidney function throughout.
Diagnosed with atypical HUS?
Our physician-led team coordinates Soliris infusion therapy closely with your nephrologist.
Call (551) 336-5580This article is for general educational purposes and is not a substitute for medical advice. Treatment decisions should always be made with your physician based on your individual diagnosis and health history.